Cited by 383Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Nakamura, Yoshiaki, Taniguchi, Hiroya, Ikeda, Masafumi, Bando, Hideaki, Kato, Ken, Morizane, Chigusa, Esaki, Taito, Komatsu, Yoshito, Kawamoto, Yasuyuki, Takahashi, Naoki, Ueno, Makoto, Kagawa, Yoshinori, Nishina, Tomohiro, Kato, Takeshi, Yamamoto, Yoshiyuki, Furuse, Junji, Denda, Tadamichi, Kawakami, Hisato, Oki, Eiji, Nakajima, Takako, Nishida, Naohiro, Yamaguchi, Kensei, Yasui, Hisateru, Goto, Masahiro, Matsuhashi, Nobuhisa, Ohtsubo, Koushiro, Yamazaki, Kentaro, Tsuji, Akihito, Okamoto, Wataru, Tsuchihara, Katsuya, Yamanaka, Takeharu, Miki, Izumi, Sakamoto, Yasutoshi, Ichiki, Hiroko, Hata, Masayuki, Yamashita, Riu, Ohtsu, Atsushi, Odegaard, Justin I., Yoshino, Takayuki·2020·Nature Medicine

DOI 10.1038/s41591-020-1063-5

Open this paper in CoChat — free account

Abstract

Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1063-5

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,783
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Integrated genomic characterization of oesophageal carcinoma
Sun, Q., Kelsen, D. P., Wiznerowicz, M., Lu, Y., Sandusky, G., Wan, Y., Weinhold, N., Wong, A. M., Carvalho, A. L., Luketich, J. D., et al. (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,869
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Self-citation
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Bañales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,397
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,159
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 593
Self-citation
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518

Show all 32 references

Research works printed but not linked: 1

Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https://arxiv.org/abs/1303.3997 (2013). · arXiv

Sorted by citations

Items 301–383 of 383

A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation
Yamashita, Y., Ishii, Y., Serikawa, M., Okamoto, W., Tsuboi, T., Tatsukawa, Y., Nakamura, S., Hirano, T., Ikemoto, J., & Oka, S. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01772-3 · Cited by 1
Self-citation
Neoadjuvant and adjuvant approaches in gastroesophageal cancers
Scheck, M. K., Masetti, M., & Lorenzen, S. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000950 · Cited by 1
Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series
Pinelli, D., Micalef, A., Merelli, B., Trezzi, R., Amaduzzi, A., Agnesi, S., Guizzetti, M., Camagni, S., Fedele, V., & Colledan, M. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100770 · Cited by 1
Biomarkers of minimal residual disease and treatment
Murray, N. P. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.002 · Cited by 1
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1 -Mutated Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer?
Okeya, A., Shimomura, A., Kitagawa, D., & Shimizu, C. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00992 · Cited by 1
Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing
Fukuda, A., Mizuno, T., Yoshida, T., Sunami, K., Kubo, T., Koyama, T., Yonemori, K., Okusaka, T., Kato, K., Ohe, Y., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf065 · Cited by 1
Self-citation
A Review of the Early Detection of Colon Cancer and the Role of Circulating Tumor DNA
Kandel, A., Thida, A. M., & Preet, M. (2025) · Cureus · doi:10.7759/cureus.84394 · Cited by 2
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification
Smith, B. K. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3509.0528 · Cited by 1
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?
Gizhlaryan, M. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0665 · Cited by 1
Clinically Meaningful Outcome Measures: A Role for Geriatric Assessment
Kovar, N. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0624 · Cited by 1
GLF6mA: A Novel Model for N6-Methyladenine DNA Methylation Identification With Gene Expression DataPreprint
Wang, Q., Song, L., Liu, W., Chen, X., Wang, X., Yang, B. F., Jiang, J., Zhou, X., Chen, G., & Lin, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4052657 · Cited by 1
Identification of Tumor Specific Neoantigens and Their Implications in Dendritic Cell Immunotherapy Using Liquid Biopsy Results: Findings from an Observational Cohort StudyPreprint
Myint, K. Z. Y., Shimabuku, M., Horio, R., Kaneda, M., Shimizu, Y., & Taguchi, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1069498/v2 · Cited by 1
ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases
Kobayashi, S., Nakamura, Y., Takahashi, S., Taniguchi, H., & Yoshino, T. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09456-9
Self-citation
In the literature: December 2020
Gambardella, V., Ibarrola‐Villava, M., Tarazona, N., & Cervantes, A. M. R. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100009
ASO Author Reflections: Impact of Liquid Biopsy Using Plasma Cell-Free DNA in Solid Tumors in Japan
Matsudera, S., Kano, Y., & Ikeda, S. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09858-3
Prognostic and Predictive Value of Circulating Tumor DNA in Patients with Advanced Colorectal Cancer and ChemotherapyPreprint
Liu, X., Xie, Y., Ou, K., Zhang, X., Lu, C., Liu, J., & Yang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-585372/v1
Conversion Surgery in Pancreatic Cancer
Saiura, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-2870-2_8
The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”
Yoshino, T. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3509.0554
Self-citation
An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer
Gong, J. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0650
Can Liquid Biopsy be Used to Explore Future Precision Medicine for Solid Tumors?
Kikuchi, H., & Takeuchi, H. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10873-7
Identification of Tumor Specific Neoantigens and Their Implications in Dendritic Cell Immunotherapy Using Liquid Biopsy Results: Findings from an Observational Cohort StudyPreprint
Myint, K. Z. Y., Shimabuku, M., Horio, R., Kaneda, M., Shimizu, Y., & Taguchi, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1069498/v1
La 'compulsión de repetición' y la 'pulsión de muerte'. Historia, Vinculación, Vicisitudes y aportes postfreudianos
González, E. H. (2012) · Americanae (AECID Library)
抗がん剤臨床開発におけるビッグデータの活用と課題
大津, 敦. (2021) · Skin Cancer · doi:10.5227/skincancer.36.181
Clinical utility of genome sequencing using liquid biopsy assay in the treatment of pancreatic cancer
Hayashi, H. (2022) · Suizo · doi:10.2958/suizo.37.14
Endoscopic ultrasound-guided tissue acquisition and gene panel testing for pancreatic cancer
Sudo, K., Kita, E., Tsujimoto, A., Nakamura, K., Odaka, A., Itami, M., Yokoi, S., & Ishii, H. (2022) · Suizo · doi:10.2958/suizo.37.8
Identification of Tumor Specific Neoantigens and Their Implications in Dendritic Cell Immunotherapy Using Liquid Biopsy Results: Findings from an Observational Cohort StudyPreprint
Myint, K. Z. Y., Shimabuku, M., Horio, R., Kaneda, M., Shimizu, Y., & Taguchi, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1069498/v3
Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer
Malla, M., & Parikh, A. R. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.02.009
Liquid Biopsy Using Cell-Free Tumor DNA for Gastrointestinal Cancers
Nakano, T., Abe, T., Takao, S., Saito, H., Masuda, T., & Mimori, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_13
Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers
Alqahtani, A. J., Yin, C., Marshall, J. L., & Noel, M. S. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.1.16
Proposing Response Evaluation Criteria in Solid Tumors Based on Genomic Profiling or Genomic RECIST: A Retrospective Study on the Liquid Biopsy Results of 29 Cancer Patients
Myint, K. Z. Y., Shimabuku, M., Kashihara, K., Horio, R., Kaneda, M., Shimizu, Y., & Taguchi, J. (2022) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079154
Circulating Tumour DNA and Risk-Stratified Surveillance Strategies for Patients with Colorectal Liver Metastases
Newhook, T. E., & Kawaguchi, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_59
Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas
Nishijima, A., Tanikawa, M., & Oda, K. (2022) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-19-4711-7_5
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri
Starling, N., & Cunningham, D. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02146-9
Data from Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer
Fujii, S., Kotani, D., Hattori, M., Nishihara, M., Shikanai, T., Hashimoto, J., Hama, Y., Nishino, T., Suzuki, M., Yoshidumi, A., et al. (2023) · doi:10.1158/1078-0432.c.6532572
Self-citation
Data from Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer
Fujii, S., Kotani, D., Hattori, M., Nishihara, M., Shikanai, T., Hashimoto, J., Hama, Y., Nishino, T., Suzuki, M., Yoshidumi, A., et al. (2023) · doi:10.1158/1078-0432.c.6532572.v1
Self-citation
Supplementary Table from Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer
Fujii, S., Kotani, D., Hattori, M., Nishihara, M., Shikanai, T., Hashimoto, J., Hama, Y., Nishino, T., Suzuki, M., Yoshidumi, A., et al. (2023) · doi:10.1158/1078-0432.22487718
Self-citation
Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team for gastrointestinal cancer chemotherapy: prospective observational study protocol of M-CAST study
Iimura, Y., Nakazawa, M., Tsuru, Y., Togashi, H., Honda, T., Baba, K., Ishibashi, M., Sasuga, C., Furukawa, N., Sato, T., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02849-6
Additional file 2 of Genomic profile of Chinese patients with endometrial carcinoma
Li, J., Li, X., Quan, C., Li, X., Wan, C., & Wu, X. (2023) · Figshare · doi:10.6084/m9.figshare.24172104
Reply to A. Okeya et al
Martín, M., & Sohn, J. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01190
Application of ctDNA in Colorectal Cancer Detection
王, 明. (2024) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2024.144062
Integrative Analysis Reveals Differential Characteristics of DDR1 Mutant and Wild-type Gastric Cancers and Constructs their Prediction Models
Tian, Y., Xie, Y., Yi, G., Yu, F., Bai, F., Wang, J., & Zhang, D. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673319260241014054643
The immunotherapy challenge in locally advanced gastroesophageal cancer: VESTIGE trial’s insights and future pathways
Nakayama, I., Nakamura, Y., & Shitara, K. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.004
Self-citation
Finding a needle in a haystack: Measures of circulating tumor DNA (ctDNA) to guide treatment decisions in oncology
Dubrovsky, G., Earland, N. J., Harris, P., Chauhan, P. S., Szymanski, J. J., Chaudhuri, A. A., Zevallos, J. P., & Lotze, M. T. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.03.022
A germline and somatic mutation sorting (GeMSort) algorithm for extracting presumed germline pathogenic variants in liquid genomic profiling: Insights from Database of Center for Cancer Genomics and Advanced Therapeutics (C-CAT)Preprint
Oda, S., Matsukawa, M., Tomozawa, C., Tanabe, N., Watanabe, T., Koyama, T., Yoshida, T., & Hirata, M. (2025) · medRxiv · doi:10.1101/2025.05.29.25327892
Intérêt de la détection de l’ADN tumoral circulant dans les cancers colorectaux en 2025
Laurent‐Puig, P. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.03.009
Circulating tumour DNA-guided second-line targeted therapy for patients with metastatic colorectal cancer after failure of first-line cetuximab-based treatment: A prospective, phase II trialPreprint
Zou, J., Yang, W., Liu, Y., Li, W., Zhang, J., Geng, Q., Chang, J., Zhu, X., Huang, M., Wang, C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7294906/v1
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)
Masuishi, T., Taniguchi, H., Kotani, D., Bando, H., Komatsu, Y., Shinozaki, E., Sunakawa, Y., Satoh, T., Nishina, T., Esaki, T., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105839
Self-citation
Cell-free DNA: history, applications, and promises
Thompson, L. M., Ibrahim, A. E., & Stein, R. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33947-9.00007-4
The Utility and Challenges of Liquid Biopsy
Kikuchi, A., Naruse, A., NONAKA, K., MORI, M., & Tsutsumiuchi, K. (2025) · Thermal Medicine · doi:10.3191/thermalmed.41.57
Additional file 2 of NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Jacobs, S. A., Wang, Y., Abraham, J., Feng, H., Montero, A. J., Lipchik, C., Finnigan, M., Jankowitz, R. C., Salkeni, M. A., Maley, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26710016
Additional file 1 of Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets
Dong, Z., Chong, W., Chen, C., Qi, L., Mengke, L., Dou, M., Jiawei, Y., Longxi, Q., Liu, H., Liu, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26688293
Additional file 1 of Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team for gastrointestinal cancer chemotherapy: prospective observational study protocol of M-CAST study
Iimura, Y., Nakazawa, M., Tsuru, Y., Togashi, H., Honda, T., Baba, K., Ishibashi, M., Sasuga, C., Furukawa, N., Sato, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23543258
Additional file 1 of NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Jacobs, S. A., Wang, Y., Abraham, J., Feng, H., Montero, A. J., Lipchik, C., Finnigan, M., Jankowitz, R. C., Salkeni, M. A., Maley, S. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26710013
Additional file 1 of Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer
Sivapalan, L., Thorn, G. J., Gadaleta, E., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Figshare · doi:10.6084/m9.figshare.19549533
Additional file 2 of Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer
Sivapalan, L., Thorn, G. J., Gadaleta, E., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Figshare · doi:10.6084/m9.figshare.19549536
Additional file 1 of Genomic profile of Chinese patients with endometrial carcinoma
Li, J., Li, X., Quan, C., Li, X., Wan, C., & Wu, X. (2023) · Figshare · doi:10.6084/m9.figshare.24172101
Multimodal artificial intelligence integrates imaging, endoscopic, and omics data for intelligent decision-making in individualized gastrointestinal tumor treatment
Nian, H., Wu, Y.-B., Bai, Y., Zhang, Z.-L., Tu, X., Liu, Q., Zhou, D.-H., & Du, Q. (2026) · Artificial Intelligence in Gastroenterology · doi:10.35712/aig.v7.i1.115498
Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling
Okuno, N., & Hara, K. (2026) · Choonpa Igaku · doi:10.3179/jjmu.jjmu.r.269
Long-term quality of life, financial toxicity, and decision regret following therapeutic and prophylactic gastrectomy for cancer
Lee, F. G., Sample, J. W., Fan, C., Vierkant, R. A., Daniel, S. K., Bowers, S. P., Wasif, N., Truty, M. J., Kendrick, M. L., Thiels, C. A., et al. (2026) · Gastric Cancer · doi:10.1007/s10120-026-01723-0
Pretreatment KRAS-Mutant Circulating Tumor DNA Predicts Incidence and Patterns of Recurrence in Patients Undergoing Radiofrequency Ablation for Colorectal Liver Metastases: A Prospective Analysis
Lin, K., Wang, C., Qiao, B., Zhang, N., Yang, D., Jin, D., Li, C., Lv, J., He, M., Lin, Z., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00858
Sensitive detection of copy number alterations in low-pass liquid biopsy sequencing data
Eriksson, L., & Lakatos, E. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag111
Cancer biology and the principles of targeted cancer drug discovery
Davies, A., Jones, G., Krishnan, S., Krishnamoorthy, M., Maruggi, M., Kaneda, M., & Marjon, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00035-2
A case of advanced esophagogastric junction cancer in which comprehensive genomic profiling by liquid biopsy led to the diagnosis of a second primary hepatocellular carcinoma
Hirotani, A., Sugimori, M., Sato, S., Miwa, H., Sato, T., Kudo, M., Morimoto, M., Kunisaki, C., & Maeda, S. (2026) · International Cancer Conference Journal · doi:10.1007/s13691-026-00860-8
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
Duan, Y., Hashimoto, T., Shibuki, T., Taniguchi, H., Sunakawa, Y., Komatsu, Y., Takahashi, N., Sato, Y., Yamaguchi, K., Nishina, T., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00971
Self-citation
Current Status and Future Perspective of Precision Medicine in Oncology
高濱, 隆., 米阪, 仁., 白石, 直., Oda, I., 池川, 敦., 西郷, 和., 福岡, 和., & 中川, 和. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.15100/00022598
Liquid Biopsies: A Window into Tumour Dynamics
Minocha, N., Pandey, P., Garima, Wilson, K., & Dhanawat, M. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814144126010006
SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies
Matsuda, K., Yuda, J., Yoshimaru, R., Harima, I., Sakuma, H., Uehara, A., Oto, M., Fukatsu, M., Ikezoe, T., Araie, H., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03049-4
Self-citation
Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway
Matsubara, Y., Wakabayashi, M., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Masuishi, T., Nishina, T., Bando, H., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.107734
Self-citation
Early screening and risk factors for gastric cancer
Jiang, J.-J., Chen, K., Weng, T., Hong, J.-M., & Qin, W.-Y. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.119127
Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study
Murano, T., Ikematsu, H., Matsuhashi, N., Tsukada, Y., Shiozawa, M., Kato, T., Oki, E., Yamaguchi, T., Kagawa, Y., Kanazawa, A., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00941
Self-citation
Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Riely, G. J., Martini, J.-F., Galicia, N. P., Tunquist, B. J., Wilner, K. D., Huang, R. S. P., Guo, C., Deng, S., Meng, W., Kiely, J., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0102
Temporal dynamics and spatial patterns of recurrence after curative gastrectomy for gastric cancer: A multicenter hazard function analysis of 3,278 patients
Chen, S., Ding, P., Guo, H., Gao, K., Gu, R., Zhang, L., Chen, Y., Shi, Y., Long, H., Meng, N., et al. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.112000
Cell-Free DNA Fragmentomics beyond Early Detection: A Narrative Review of Treatment Monitoring Applications in Solid Tumors
Aakash, M., Premkumar, G., & Venkateswaramurthy, N. (2026) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2026.00033
Single-center Experience with Comprehensive Genomic Profiling Using Circulating Tumor DNA for Metastatic Colorectal Cancer
Ito, K., Kataoka, K., Muroi, Y., Koba, M., Fukumoto, Y., Imada, A., Song, J., Rao, Z., Osumi, H., Uchino, M., et al. (2026) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2026-003
Self-citation
Circulating Tumor DNA-Guided Adjuvant and Post-Adjuvant Therapy in Resected Colorectal Cancer: From Molecular Residual Disease Detection to Proven Clinical Utility
Koo, T. H., Chowdhary, R., Arora, K., Lai, K. C. L., & Zakaria, A. D. (2026) · Biomedicines · doi:10.3390/biomedicines14081674
Liquid Biopsy in Biliary Tract Cancer: When Tissue Is Not Enough
Au, L., & Tie, J. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-2090
Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies
Sagawa, T., Hirakawa, M., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01586-9
Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers
Masui, Y., Yoshida, T., Yamaguchi, Y., Miyakoshi, J., Higashiyama, R. I., Tateishi, A., Shinno, Y., Matsumoto, Y., Okuma, Y., Mizutani, T., et al. (2026) · Cancer Science · doi:10.1111/cas.70538
Assessment of MRD and Longitudinal Monitoring of Post‐Surgery Biliary Tract Cancer With a Customized ctDNA Panel
Shinohara, Y., Nakamura, T., Kimura, Y., Murakami, T., Kojima, S., Yamaguchi, T., Hatanaka, K. C., Okazaki, R., Kitayama, Y., Fukuda, K., et al. (2026) · Cancer Science · doi:10.1111/cas.70552
Self-citation
Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial
Nakamura, Y., Esaki, T., Nishina, T., Shinozaki, E., Taniguchi, H., Kato, T., Komatsu, Y., Yuki, S., Kato, K., Wakabayashi, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108578
Self-citation
ctDNA retesting to guide anti-EGFR therapy in later-line metastatic colorectal cancer
Mešinová, S., Streško, M., Šebest, L., Repiská, V., Danisovic, L., & Behulová, R. L. (2026) · Neoplasma · doi:10.4149/neo_2026_260622n206
Redefining Curative-Intent Treatment for Colorectal Liver Metastases: Surgical and Multidisciplinary Decision-Making—A Systematic Review
Burasakarn, P., Ponghussaban, K., Chalokool, V., Thienhiran, A., Hongjinda, S., & Fuengfoo, P. (2026) · Livers · doi:10.3390/livers6060112
The Modern Continuum of Care for Colorectal Liver Metastases: A Comprehensive Review
Burasakarn, P., Ponghussaban, K., Chalokool, V., Thienhiran, A., Hongjinda, S., & Fuengfoo, P. (2026) · The American Surgeon · doi:10.1177/00031348261504348

Authors: Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., Ueno, M., Kagawa, Y., Nishina, T., Kato, T., Yamamoto, Y., Furuse, J., Denda, T., Kawakami, H., Oki, E., Nakajima, T., Nishida, N., Yamaguchi, K., Yasui, H., Goto, M., Matsuhashi, N., Ohtsubo, K., Yamazaki, K., Tsuji, A., Okamoto, W., Tsuchihara, K., Yamanaka, T., Miki, I., Sakamoto, Y., Ichiki, H., Hata, M., Yamashita, R., Ohtsu, A., Odegaard, J. I., & Yoshino, T.
Affiliations: National Cancer Center Hospital East (JP)
Aichi Cancer Center (JP)
National Cancer Center Hospital (JP)
National Hospital Organization Kyushu Cancer Center (JP)
Hokkaido University Hospital (JP)
Saitama Cancer Center (JP)
Kanagawa Cancer Center (JP)
Kansai Rosai Hospital (JP)
Shikoku Cancer Center (JP)
Osaka National Hospital (JP)
University of Tsukuba Hospital (JP)
Kyorin University Hospital (JP)
Chiba Cancer Center (JP)
Kindai University Hospital (JP)
Kyushu University (JP)
St. Marianna University School of Medicine (JP)
The University of Osaka (JP)
The Cancer Institute Hospital (JP)
Kobe Medical Center (JP)
Osaka Medical and Pharmaceutical University Hospital (JP)
Gifu University (JP)
Kanazawa University (JP)
Shizuoka Cancer Center (JP)
Kagawa University Hospital (JP)
Hiroshima University Hospital (JP)
Guardant (United States) (US)
Corresponding author: Yoshino, Takayuki
ORCID: Nakamura, Yoshiaki
Taniguchi, Hiroya
Ikeda, Masafumi
Bando, Hideaki
Kato, Ken
Morizane, Chigusa
Esaki, Taito
Komatsu, Yoshito
Kawamoto, Yasuyuki
Takahashi, Naoki
Ueno, Makoto
Kagawa, Yoshinori
Nishina, Tomohiro
Kato, Takeshi
Yamamoto, Yoshiyuki
Furuse, Junji
Denda, Tadamichi
Kawakami, Hisato
Oki, Eiji
Nakajima, Takako
Nishida, Naohiro
Yamaguchi, Kensei
Yasui, Hisateru
Goto, Masahiro
Matsuhashi, Nobuhisa
Ohtsubo, Koushiro
Yamazaki, Kentaro
Tsuji, Akihito
Okamoto, Wataru
Tsuchihara, Katsuya
Yamanaka, Takeharu
Sakamoto, Yasutoshi
Ichiki, Hiroko
Yamashita, Riu
Ohtsu, Atsushi
Odegaard, Justin I.
Yoshino, Takayuki
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2020-10-05
Volume: 26
Issue: 12
Pages: 1859-1864
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-020-1063-5
OpenAlex: W3089353724
Cited by: 373
References: 32
Citations by year: 2026: 41 · 2025: 57 · 2024: 60 · 2023: 71 · 2022: 73 · 2021: 67 · 2020: 3
FWCI: 18.33
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: circulating tumor DNA, liquid biopsy, advanced gastrointestinal cancer, clinical trial recruitment, clonal architecture, oncogenic drivers, precision medicine
MeSH terms: Circulating Tumor DNA, Adult, DNA, Neoplasm, Gastrointestinal Neoplasms, Genotype, Humans, Japan, Male, Middle Aged, Mutation, Biomarkers, Tumor, Precision Medicine, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks